Covaxin, Bharat Biotech's COVID-19 Vaccine's Phase 2 Data In Lancet Magazine

The report, released on March 9 said that the vaccine developed by Hyderabadbased Bharat Biotech showed better reactogenicity safety outcomes enhanced humoral cellmediated immune responses compared with the Phase 1 trials.

Author: Team Latestly